Big pharma, Partnering, Pharma

Boehringer Ingelheim partners with Hydra Biosciences for small-molecule TRP inhibitors

Posted on 14 April 2015

Tags: , ,

Hydra Biosciences and Boehringer Ingelheim have entered into a worldwide research collaboration and license agreement to identify small-molecule TRP inhibitors, with a primary focus on the treatment of renal diseases and disorders.

Under the terms of the collaboration agreement, the companies will work together to identify and advance candidate inhibitors.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

Boehringer Ingelheim is responsible for the global development and commercialization of the inhibitors that come from the collaboration.

Hydra will receive an undisclosed upfront payment, additional research funding, and the Company is eligible to receive milestone payments and tiered royalty payments on future product sales.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2015

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply